Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

venous thromboembolism

- PMLiVE

IQWiG unimpressed with Cosentyx in two new indications

Concludes Novartis drug has no added benefit in ankylosing spondylitis or psoriatic arthritis

Bayer symbol

Bayer picks strategy head for top post

Werner Baumann will take over from Dr Marijn Dekkers

- PMLiVE

ViiV and Janssen take long-acting HIV regimen into phase III

Cabotegravir and rilpivirine injectable-therapy tipped as future blockbuster

- PMLiVE

Searching for health

Janssen France’s Emmanuelle Quiles on finding ways to produce pharma innovations in a challenging environment

Bayer symbol

Bayer gets first approval for Kogenate upgrade Kovaltry

First worldwide licence for the haemophilia treatment

- PMLiVE

Sustainable solutions

Bayer's Alex Moscho on working towards long-term answers in healthcare

How Bayer transformed its approach to digital

Head of digital development Jessica Federer on how the company built digital into its DNA

- PMLiVE

ViiV and Janssen plan pivotal trials of monthly HIV treatment

Rilpivirine – cabotegravir combination could provide a monthly option

- PMLiVE

The world is our laboratory

Janssen's Thomas Stark on his company's approach to innovation, collaboration and research

- PMLiVE

Bayer forms JV with gene editing firm CRISPR

$300m investment to find new therapies for blood disorders, blindness and congenital heart disease

EU flag

Nine positive opinions for new drugs at CHMP meeting

Tagrisso, Zurampic and Portrazza among the latest recommendations

- PMLiVE

Bayer defends Xarelto as pivotal trial scrutinised

ROCKET AF trial results questioned after some INRATIO devices used in testing recalled

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links